Small dense low-density lipoprotein in primary biliary cholangitis: Independent association with metabolic syndrome
World Journal of Hepatology · 27.08.2026 · 18 (8)
DOI: 10.4254/wjh.124436 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 27.08.2026. Verfasst von Tomas Koky und 8 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Primary biliary cholangitis (PBC) is frequently associated with cholestasis-driven hypercholesterolemia characterized by lipoprotein X accumulation. Despite markedly elevated cholesterol levels, cardiovascular risk in PBC is not consistently increased, suggesting that conventional lipid parameters may inadequately reflect true atherogenic burden. Small dense low-density lipoprotein (sdLDL), a highly atherogenic low-density lipoprotein (LDL) subfraction closely linked to insulin resistance and metabolic syndrome (MetS), has not been systematically evaluated in PBC. AIM To evaluate determinants of sdLDL levels in PBC, focusing on MetS, metabolic dysfunction-associated steatotic liver disease (MASLD), liver fibrosis, and biochemical response, and assess whether sdLDL reflects metabolic dysfunction rather than cholestatic disease severity. METHODS In this cross-sectional study, 148 consecutive patients with PBC were recruited from a tertiary hepatology center. sdLDL was quantified using the Lipoprint® LDL System. MetS was defined according to International Diabetes Federation criteria. Hepatic steatosis and fibrosis were assessed using vibration-controlled transient elastography. Multivariable linear and logistic regression analyses were performed to evaluate independent determinants of sdLDL. RESULTS MetS was present in 39.2% of patients. sdLDL levels were significantly higher in patients with MetS (P = 0.004). In multivariable analysis, MetS remained independently associated with ln-transformed sdLDL levels [B = 0.76; 95% confidence interval (CI): 0.26-1.26; P = 0.003] and with the presence of detectable sdLDL (odds ratio 2.10; 95%CI: 1.02-4.35; P = 0.045), independent of age, sex, adiposity, and lipid-lowering therapy. In contrast, MASLD, advanced fibrosis, and cholestatic activity were not independently associated with sdLDL. Notably, LDL-C levels were lower in patients with MetS, whereas sdLDL and sdLDL/largeLDL ratio were significantly increased, suggesting discordance between conventional LDL-C and qualitative lipoprotein remodeling. CONCLUSION In PBC, sdLDL appears to reflect superimposed metabolic dysfunction rather than cholestatic liver disease severity. Advanced lipoprotein profiling may therefore help distinguish metabolically driven atherogenic dyslipidemia from cholestatic hypercholesterolemia in contemporary PBC cohorts.
Zitieren
APA
Koky, T., Drazilova, S., Janicko, M., Harhovsky, M., Hubkova, B., Tothova, I., Rabajdova, M., Marekova, M., & Jarcuska, P. (2026). Small dense low-density lipoprotein in primary biliary cholangitis: Independent association with metabolic syndrome. World Journal of Hepatology, 18(8). https://doi.org/10.4254/wjh.124436
Vancouver
Koky T, Drazilova S, Janicko M, Harhovsky M, Hubkova B, Tothova I, et al. Small dense low-density lipoprotein in primary biliary cholangitis: Independent association with metabolic syndrome. World Journal of Hepatology. 2026;18(8). doi:10.4254/wjh.124436
BibTeX
@article{Koky2026,
author = {Koky, Tomas and Drazilova, Sylvia and Janicko, Martin and Harhovsky, Martin and Hubkova, Beata and Tothova, Ivana and Rabajdova, Miroslava and Marekova, Maria and Jarcuska, Peter},
title = {Small dense low-density lipoprotein in primary biliary cholangitis: Independent association with metabolic syndrome},
journal = {World Journal of Hepatology},
year = {2026},
volume = {18},
number = {8},
doi = {10.4254/wjh.124436}
}
EUVIMED